3 Asian Stocks Estimated To Be Trading At Discounts Up To 39.2%

Simply Wall St

Sun, November 2, 2025 at 11:37 PM EST 4 min read

As global markets navigate a complex landscape marked by mixed performances and geopolitical developments, Asia’s stock markets present intriguing opportunities for investors. With Japan’s record highs and China’s cautious optimism amid trade discussions, identifying undervalued stocks becomes crucial in capitalizing on potential market inefficiencies. In this context, understanding the fundamentals that make a stock undervalued—such as strong financial health, growth potential, and favorable market conditions—can guide investors in making informed decisions.

Click here to see the full list of 268 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let’s explore several standout options from the results in the screener.

Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on the research, development, and commercialization of drugs for central nervous system disorders, with a market cap of ₩9.05 trillion.

Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, which reported ₩620.28 million.

Estimated Discount To Fair Value: 39.2%

SK Biopharmaceuticals is trading at ₩115,500, significantly below its estimated fair value of ₩189,933.83. Earnings have grown very large over the past year and are forecast to grow 22.7% annually, with revenue expected to increase by 23.4% per year—outpacing the Korean market’s growth rate. Recent strategic alliances, such as the joint venture with Eurofarma for AI-based epilepsy management platforms, enhance its digital healthcare expansion potential beyond traditional pharmaceuticals.

• In light of our recent growth report, it seems possible that SK Biopharmaceuticals’ financial performance will exceed current levels.

• Take a closer look at SK Biopharmaceuticals’ balance sheet health here in our report.

Overview: Innovent Biologics, Inc. is a biopharmaceutical company focused on the research and development of antibody and protein medicine products in China, the United States, and internationally, with a market cap of HK$149.08 billion.